GlassScriptPhysician profile
Leah Mickelson Macklin
NPI 1184004103
$2,478.07
in general payments reported to CMS, 2019-2025
34 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.36 · 2022: $634 · 2023: $435 · 2024: $576 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.56 |
| Education | $178.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.23 | 2022-2025 | |
| Astellas Pharma US INC | $292.23 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $226.22 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $152.42 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $149.56 | 2022-2025 | Ozempic, Rybelsus |
| Neos Therapeutics, LP | $149.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.11 | 2023-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $98.99 | 2022-2023 | Spravato |
| Lilly USA, LLC | $98.08 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $96.69 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.90 | 2024-2025 | Caplyta |
| Coloplast Corp | $76.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $66.90 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $56.94 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $51.68 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.36 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.88 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $43.12 | 2023-2025 | |
| Boston Scientific Corporation | $39.75 | 2022 | |
| Glaxosmithkline, LLC. | $38.61 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Saluda Medical Americas, INC. | $25.57 | 2024 | Evoke |
| Teva Pharmaceuticals USA, INC. | $20.63 | 2022 | |
| Dexcom, INC. | $19.56 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.23 | 2024 | Interstim |
| Axsome Therapeutics, INC. | $17.12 | 2025 | Auvelity |
| Vbi Vaccine (Delaware) INC. | $16.76 | 2023 | Prehevbrio |
| Inspire Medical Systems, INC. | $16.76 | 2025 | Inspire |
| Daiichi Sankyo INC. | $16.71 | 2023 | Injectafer |
| Currax Pharmaceuticals LLC | $16.45 | 2023 | Contrave, Onzetra Xsail |
| Horizon Therapeutics Plc | $15.64 | 2022 | |
| Alk-Abello, INC | $15.57 | 2024 | Grastek, Odactra, Ragwitek |
| Corcept Therapeutics | $14.44 | 2024 | Korlym |
| Vivus LLC | $13.89 | 2024 | Qsymia |
| Novartis Pharmaceuticals Corporation | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Macklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.